Search research articles
Contact Us
Filters
Showing results (221-230 of 233) with videos related to
Page
of 24
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group]
H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
May 5, 1999
Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria
N Miyanaga, H Akaza, T Tsukamoto, et al.
Urology
|
August 12, 1999
Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities
K Akakura, S Isaka, S Akimoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]
H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
April 16, 1998
Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study
M Kuriyama, K Ueno, H Uno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies
R Ohno, Y Yamaguchi, T Toge, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
December 5, 1998
[Phase I study of raltitrexed (ZD-1694)]
N Horikoshi, K Aiba, M Fukuoka, et al.
Hinyokika Kiyo. Acta Urologica Japonica
|
December 16, 1998
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"]
K Imai, H Yamanaka, Y Kubota, et al.
Japanese Journal of Clinical Oncology
|
March 18, 2000
Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group
T Kotake, M Usami, H Akaza, et al.
Hinyokika Kiyo. Acta Urologica Japonica
|
February 1, 1996
[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer]
T Kotake, M Usami, S Isaka, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 233) with videos related to
Sort By:
Page
of 24
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group]
H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
May 5, 1999
Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria
N Miyanaga, H Akaza, T Tsukamoto, et al.
Urology
|
August 12, 1999
Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities
K Akakura, S Isaka, S Akimoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
May 1, 1997
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group]
H Akaza, N Miyanaga, T Tsukamoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
April 16, 1998
Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study
M Kuriyama, K Ueno, H Uno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2000
A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies
R Ohno, Y Yamaguchi, T Toge, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
December 5, 1998
[Phase I study of raltitrexed (ZD-1694)]
N Horikoshi, K Aiba, M Fukuoka, et al.
Hinyokika Kiyo. Acta Urologica Japonica
|
December 16, 1998
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"]
K Imai, H Yamanaka, Y Kubota, et al.
Japanese Journal of Clinical Oncology
|
March 18, 2000
Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group
T Kotake, M Usami, H Akaza, et al.
Hinyokika Kiyo. Acta Urologica Japonica
|
February 1, 1996
[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer]
T Kotake, M Usami, S Isaka, et al.
Page
of 24